دورية أكاديمية
SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May-June, 2021.
| العنوان: | SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May-June, 2021. |
|---|---|
| المؤلفون: | Konu YR; Bordeaux Population Health Centre, UMR 1219, University of Bordeaux, National Institute for Health and Medical Research (INSERM), Research Institute for Sustainable Development (IRD), Bordeaux, France.; Département de Santé Publique, Université de Lomé, Lomé, Togo.; Centre de Recherche et de Formation en Santé Publique (CFRSP), Université de Lomé, Lomé, Togo.; Centre Africain de Recherche en Epidémiologie et en Santé Publique (CARESP), Lomé, Togo., Condé S; Togo Office, World Health Organization (WHO), Lomé, Togo., Gbeasor-Komlanvi F; Département de Santé Publique, Université de Lomé, Lomé, Togo.; Centre de Recherche et de Formation en Santé Publique (CFRSP), Université de Lomé, Lomé, Togo.; Centre Africain de Recherche en Epidémiologie et en Santé Publique (CARESP), Lomé, Togo., Sadio AJ; Département de Santé Publique, Université de Lomé, Lomé, Togo.; Centre de Recherche et de Formation en Santé Publique (CFRSP), Université de Lomé, Lomé, Togo.; Centre Africain de Recherche en Epidémiologie et en Santé Publique (CARESP), Lomé, Togo., Tchankoni MK; Département de Santé Publique, Université de Lomé, Lomé, Togo.; Centre de Recherche et de Formation en Santé Publique (CFRSP), Université de Lomé, Lomé, Togo.; Centre Africain de Recherche en Epidémiologie et en Santé Publique (CARESP), Lomé, Togo., Anani J; Togo Office, World Health Organization (WHO), Lomé, Togo., Bitty-Anderson A; Bordeaux Population Health Centre, UMR 1219, University of Bordeaux, National Institute for Health and Medical Research (INSERM), Research Institute for Sustainable Development (IRD), Bordeaux, France.; Centre Africain de Recherche en Epidémiologie et en Santé Publique (CARESP), Lomé, Togo., Mirindi BR; Togo Office, World Health Organization (WHO), Lomé, Togo., Diallo FBT; Togo Office, World Health Organization (WHO), Lomé, Togo., MIjiyawa M; Ministère de la Santé, de l'Hygiène Publique et de l'accès universel aux soins, Lomé, Togo., Dagnra AC; Laboratoire de Biologie Moléculaire et d'Immunologie (BIOLIM), Université de Lomé, Lomé, Togo., Ekouevi DK; Bordeaux Population Health Centre, UMR 1219, University of Bordeaux, National Institute for Health and Medical Research (INSERM), Research Institute for Sustainable Development (IRD), Bordeaux, France. didier.ekouevi@gmail.com.; Département de Santé Publique, Université de Lomé, Lomé, Togo. didier.ekouevi@gmail.com.; Centre de Recherche et de Formation en Santé Publique (CFRSP), Université de Lomé, Lomé, Togo. didier.ekouevi@gmail.com.; Centre Africain de Recherche en Epidémiologie et en Santé Publique (CARESP), Lomé, Togo. didier.ekouevi@gmail.com. |
| المصدر: | BMC public health [BMC Public Health] 2022 Dec 08; Vol. 22 (1), pp. 2294. Date of Electronic Publication: 2022 Dec 08. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 100968562 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2458 (Electronic) Linking ISSN: 14712458 NLM ISO Abbreviation: BMC Public Health Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central, [2001- |
| مواضيع طبية MeSH: | SARS-CoV-2* , COVID-19*/epidemiology, Young Adult ; Humans ; Child, Preschool ; Seroepidemiologic Studies ; Cross-Sectional Studies ; Antibodies, Viral |
| مستخلص: | Background: The extent of SARS-CoV-2 circulation in African countries is still unclear. Seroprevalence studies are a common approach to epidemiological surveillance, allowing estimation of the proportion of people who have had contact with the virus. We aimed at estimating the seroprevalence of anti-SARS-CoV-2 antibodies and associated factors in Togo at the national level in 2021 according to age groups, gender, and place of residence (rural or urban). Methods: From 15 May to 31 June 2021, we conducted a nationally representative cross-sectional serological survey in 12 health districts (two districts per health region) in the > 5 years old population in Togo. The Wantai SARS-CoV-2 total antibody assay S protein receptor-binding domain-based ELISA (Wantai Biological Pharmacy Enterprise Co.; Beijing, China) was used to determine the presence of SARS-CoV-2 total antibodies in plasma. Crude and weighted seroprevalences (weighted by age, sex and place of residence) were calculated and then weighted seroprevalences were adjusted according to sensitivity and specificity of the ELISA test. Finally, logistic regression models were performed in order to describe factors associated. Results: Of the 7593 participants, the overall weighted and adjusted seroprevalence of total anti-SARS-CoV-2 antibodies was 65.5% (CI95%: 18.9-21.1). Urban dwellers, young adults (30-49 years) and vaccinated individuals were significantly more likely to be seropositive. Conclusion: The high seroprevalence we observed is consistent with observations across West Africa. Quantification of the level of immunity in the population is needed to know how close we are to herd immunity. In the meantime, vaccination against the COVID-19 remains necessary. (© 2022. The Author(s).) |
| التعليقات: | Erratum in: BMC Public Health. 2023 Jan 27;23(1):185. (PMID: 36707780) |
| References: | WHO Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int . [cited 26 Apr 2022]. Alwan NA. Surveillance is underestimating the burden of the COVID-19 pandemic. Lancet. 2020;396(10252):e24. https://doi.org/10.1016/S0140-6736(20)31823-7 . (PMID: 10.1016/S0140-6736(20)31823-7) Adebisi YA, Rabe A, Lucero-Prisno Iii DE. COVID-19 surveillance systems in African countries. Health Promot Perspect. 2021;11(4):382–92. https://doi.org/10.34172/hpp.2021.49 . (PMID: 10.34172/hpp.2021.49) Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, Li Z, Ma X, Valenciano M, Cheng B, Al Ariqi L, Rashidian A, Okeibunor J, Azim T, Wijesinghe P, Le LV, Vaughan A, Pebody R, Vicari A, Yan T, Yanes-Lane M, Cao C, Clifton DA, Cheng MP, Papenburg J, Buckeridge D, Bobrovitz N, Arora RK, Van Kerkhove MD; Unity Studies Collaborator Group. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Med. 2022;19(11):e1004107. https://doi.org/10.1371/journal.pmed.1004107 . Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0252617. https://doi.org/10.1371/journal.pone.0252617 . (PMID: 10.1371/journal.pone.0252617) McConnell D, Hickey C, Bargary N, Trela-Larsen L, Walsh C, Barry M, et al. Understanding the challenges and uncertainties of Seroprevalence studies for SARS-CoV-2. Int J Environ Res Public Health. 2021;18(9):4640. https://doi.org/10.3390/ijerph18094640 . (PMID: 10.3390/ijerph18094640) Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. https://doi.org/10.1038/s41591-021-01377-8 . (PMID: 10.1038/s41591-021-01377-8) Hossain A, Nasrullah SM, Tasnim Z, Hasan MK, Hasan MM. Seroprevalence of SARS-CoV-2 IgG antibodies among health care workers prior to vaccine administration in Europe, the USA and East Asia: a systematic review and meta-analysis. EClinicalMedicine. 2021;33:100770. https://doi.org/10.1016/j.eclinm.2021.100770 . (PMID: 10.1016/j.eclinm.2021.100770) Bergeri I, Lewis HC, Subissi L, Nardone A, Valenciano M, Cheng B, et al. Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic. Influenza Other Respir Viruses. 2022;16(1):7–13. https://doi.org/10.1111/irv.12915 . (PMID: 10.1111/irv.12915) Halatoko WA, Konu YR, Gbeasor-Komlanvi FA, Sadio AJ, Tchankoni MK, Komlanvi KS, et al. Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020. PLoS One. 2020;15(11):e0242124. https://doi.org/10.1371/journal.pone.0242124 . (PMID: 10.1371/journal.pone.0242124) Programme des Nations Unies pour le Développement (PNUD). A propos du Togo. Le PNUD au Togo. Available from: https://www.tg.undp.org/content/togo/fr/home/countryinfo.html . [cited 22 Jun 2020]. United Nations Development Program (UNDP). Human Development Report 2019. New York: UNDP; 2019. p. 366. Available from: http://hdr.undp.org/sites/default/files/hdr2019.pdf [cited 22 Jun 2020]. (PMID: 10.18356/838f78fd-en) Standardized Monitoring and Assessment of Relief and Transitions (SMART) Methodology. Sampling for SMART including considerations for urban sampling. SMART Methodology. Available from: https://smartmethodology.org/survey-planning-tools/smart-methodology/smart-methodology-paper/ . [cited 3 Nov 2022]. World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection, 26 May 2020. Geneva: World Health Organization; 2020. Report No.: WHO/2019-nCoV/Seroepidemiology/2020.2. Available from: https://apps.who.int/iris/handle/10665/332188 . [cited 26 Apr 2022]. US Food and Drug Administration. WANTAI SARS-CoV-2 Ab ELISA - Instructions for Use. 2020. Available from: https://www.fda.gov/media/140929/download [cited 26 Apr 2022]. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978;107(1):71–6. https://doi.org/10.1093/oxfordjournals.aje.a112510 . (PMID: 10.1093/oxfordjournals.aje.a112510) Donkor IO, Akorli J, Abuaku B, Opoku M, Andoh NE, Mensah SK, et al. SARS CoV2 Seroprevalence in rural and urban populations in Ghana. Geneva: Zenodo; 2021. Available from: https://zenodo.org/record/5771207 . [cited 28 Apr 2022]. Kolawole O, Tomori O, Agbonlahor D, Ekanem E, Bakare R, Nasidi A, et al. Population-based age-stratified Seroprevalence investigation on SARS-CoV-2 virus in selected states of high and low burden of disease in Nigeria. Geneva: Zenodo; 2021. Available from: https://zenodo.org/record/5644223 . [cited 28 Apr 2022]. Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, et al. SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. medRxiv; 2022. p. 2022.02.14.22270934. Available from: https://www.medrxiv.org/content/10.1101/2022.02.14.22270934v1 [cited 8 Apr 2022]. Chisale MRO, Ramazanu S, Mwale SE, Kumwenda P, Chipeta M, Kaminga AC, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: a systematic review and meta-analysis. Rev Med Virol. 2022;32(2):e2271. https://doi.org/10.1002/rmv.2271 . (PMID: 10.1002/rmv.2271) Steinhardt LC, Ige F, Iriemenam NC, Greby SM, Hamada Y, Uwandu M, et al. Cross-reactivity of two SARS-CoV-2 serological assays in a setting where malaria is endemic. J Clin Microbiol. 2021;59(7):e0051421. https://doi.org/10.1128/JCM.00514-21 . (PMID: 10.1128/JCM.00514-21) Lapidus S, Liu F, Casanovas-Massana A, Dai Y, Huck JD, Lucas C, et al. Plasmodium infection induces cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein. MedRxiv Prepr Serv Health Sci. 2021:2021.05.10.21256855. https://doi.org/10.1101/2021.05.10.21256855 . Dorkenoo AM, Gbeasor-Komlanvi FA, Gbada K, Zida-Compaore WIC, Teou D, Konu YR, et al. Prevalence of malaria and Covid-19 in febrile patients in Lomé, Togo in 2020. Acta Parasitol. 2022;67(3):1335–42. https://doi.org/10.1007/s11686-022-00586-6 . (PMID: 10.1007/s11686-022-00586-6) Soumah AA, Diallo MSK, Guichet E, Maman D, Thaurignac G, Keita AK, et al. High and rapid increase in seroprevalence for SARS-CoV-2 in Conakry, Guinea: results from three successive cross-sectional surveys (ANRS COV16-ARIACOV). Open Forum Infect Dis Ther. 2022:ofac152. https://doi.org/10.1093/ofid/ofac152 . Covid-19, un an après : persistance des anticorps protecteurs et réduction significative du risque de réinfection. Institut Pasteur 2021 Available from: https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-apres-persistance-anticorps-protecteurs-reduction-significative-du-risque-reinfection [cited 26 Apr 2022]. Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19. Available from: https://www.who.int/news-room/questions-and-answers/item/herd-immunity-lockdowns-and-covid-19 [cited 26 Apr 2022]. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19). Oxford: Our World Data; 2020. Available from: https://ourworldindata.org/covid-vaccinations . [cited 23 Sep 2022]. Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and Meta-analysis. JAMA Netw Open. 2021;4(12):e2137257. https://doi.org/10.1001/jamanetworkopen.2021.37257 . (PMID: 10.1001/jamanetworkopen.2021.37257) Kleynhans J, Tempia S, Wolter N, von Gottberg A, Bhiman JN, Buys A, et al. SARS-CoV-2 Seroprevalence in a rural and urban household cohort during first and second waves of infections, South Africa, July 2020-march 2021. Emerg Infect Dis. 2021;27(12):3020–9. https://doi.org/10.3201/eid2712.211465 . (PMID: 10.3201/eid2712.211465) Sempos CT, Tian L. Adjusting coronavirus prevalence estimates for laboratory test kit error. Am J Epidemiol. 2020;190(1):109–15. https://doi.org/10.1093/aje/kwaa174 . (PMID: 10.1093/aje/kwaa174) |
| معلومات مُعتمدة: | 001 International WHO_ World Health Organization; DF/AAP 2022-1 Agence Nationale de Recherches sur le Sida et les Hépatites Virales |
| فهرسة مساهمة: | Keywords: General population; SARS-CoV-2; Seroprevalence; Togo |
| المشرفين على المادة: | 0 (Antibodies, Viral) |
| تواريخ الأحداث: | Date Created: 20221208 Date Completed: 20221215 Latest Revision: 20230305 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9730644 |
| DOI: | 10.1186/s12889-022-14794-2 |
| PMID: | 36476149 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1471-2458 |
|---|---|
| DOI: | 10.1186/s12889-022-14794-2 |